Patent · US Active

Tissue targeted immunotolerance with a CD39 effector

US11981715B2 · kind B2 · utility

0Cited by
110References
7Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 18, 2021
Grant dateMay 14, 2024
Priority date—
Expiry dateMay 24, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/33
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Methods and compounds for conferring site-specific or local immune privilege, such as to the skin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.